Sandbox:Affan: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) No edit summary |
Aditya Ganti (talk | contribs) No edit summary |
||
Line 175: | Line 175: | ||
|- | |- | ||
! | ! | ||
! colspan="2" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" + | | ! colspan="2" rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" + |Oral lesions | ||
! rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" + |Characterestic features | ! rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" + |Characterestic features | ||
! rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" + |Associated conditions | ! rowspan="1" style="background:#4479BA; color: #FFFFFF;" align="center" + |Associated conditions | ||
Line 183: | Line 183: | ||
|- | |- | ||
| rowspan="13" |Pigmented lesions | | rowspan="13" |Pigmented lesions | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Ephelis | * Ephelis | ||
| | | | ||
| | | | ||
Line 192: | Line 191: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Oral melanocytic macule | * Oral melanocytic macule | ||
| | | | ||
| | | | ||
Line 201: | Line 199: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Melanocytic nevus | * Melanocytic nevus | ||
| | | | ||
| | | | ||
Line 210: | Line 207: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Oral melanoacanthoma | * Oral melanoacanthoma | ||
| | | | ||
| | | | ||
Line 219: | Line 215: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Smoker's melanosis | * Smoker's melanosis | ||
| | | | ||
| | | | ||
Line 228: | Line 223: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Melanoma | * Melanoma | ||
| | | | ||
| | | | ||
Line 237: | Line 231: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Kaposi sarcoma | * Kaposi sarcoma | ||
| | | | ||
| | | | ||
Line 246: | Line 239: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Addison's disease | * Addison's disease | ||
| | | | ||
| | | | ||
Line 255: | Line 247: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Peutz jeghers syndrome | * Peutz jeghers syndrome | ||
| | | | ||
| | | | ||
Line 264: | Line 255: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Neurofibromatosis | * Neurofibromatosis | ||
| | | | ||
| | | | ||
Line 273: | Line 263: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Polyostotic fibrous dysplasia | * Polyostotic fibrous dysplasia | ||
| | | | ||
| | | | ||
Line 282: | Line 271: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Medication induced pigmentation | * Medication induced pigmentation | ||
| | | | ||
| | | | ||
Line 291: | Line 279: | ||
| | | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* Amalgam tattoo | * Amalgam tattoo | ||
| | | | ||
| | | |
Revision as of 16:53, 11 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Muhammad Affan M.D.[2]
Surface oral lesions | ||||||||
---|---|---|---|---|---|---|---|---|
Oral lesions | Appearance | Associated conditions | Location | Microscopic | Image | |||
White Lesions | Leukoedema |
|
|
|
|
|||
Fordyce granules |
|
|
|
|
||||
Benign migratoy glossitis |
|
|
|
|
||||
Hairy tongue |
|
|
|
|
||||
Hairy leukoplakia |
White patches
|
|
|
|
||||
White sponge nevus |
|
|
|
|||||
Lichen Planus |
|
|
|
|
||||
Frictional hyperkeratosis |
|
|
|
|
||||
Leukoplakia |
|
|
|
|
||||
Erythroplakia |
|
|
|
|
||||
Oral lesions | Characterestic features | Associated conditions | Location | Microscopic | Image | |||
Pigmented lesions |
|
|||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
Vesicular/Ulcerative oral lesions | Symptoms | characterestic features | Associated conditions | Location | Image | |||
Infections | ||||||||
Autoimmune conditions | ||||||||
Idiopathic conditions | ||||||||
Soft tissue oral lesions | ||||||
---|---|---|---|---|---|---|
Reactive lesions | Symptoms | Characterstic features | Associated conditions | Location | Image | |
|
||||||
|
||||||
|
||||||
|
||||||
|
||||||
|
||||||
|
||||||
Tumors | etiology | location | Clinical appearance | Gold standard/Diagnosis | Image | |
Benign tumors |
|
|||||
|
||||||
|
||||||
Malignant tumors |
|
|||||
|
||||||
|
||||||
|
||||||
Cysts |
|
|||||
|
||||||
|
||||||
|
||||||
|